595 related articles for article (PubMed ID: 30415435)
21. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
[No Abstract] [Full Text] [Related]
22. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.
Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG
PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384
[TBL] [Abstract][Full Text] [Related]
23. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
24. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
25. On the histogenesis and morphology of ovarian carcinomas.
Dallenbach-Hellweg G
J Cancer Res Clin Oncol; 1984; 107(2):71-80. PubMed ID: 6715398
[TBL] [Abstract][Full Text] [Related]
26. Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma.
Tian Q; Lu B; Ye J; Lu W; Xie X; Wang X
J Int Med Res; 2016 Apr; 44(2):357-66. PubMed ID: 26880793
[TBL] [Abstract][Full Text] [Related]
27. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic features of ovarian neoplasms with emphasis on borderline ovarian tumors: an institutional perspective.
Hashmi AA; Hussain ZF; Bhagwani AR; Edhi MM; Faridi N; Hussain SD; Khan M
BMC Res Notes; 2016 Apr; 9():205. PubMed ID: 27052022
[TBL] [Abstract][Full Text] [Related]
29. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
30. Ovarian tumors: a survey of selected advances of note during the life of this journal.
Young RH
Hum Pathol; 2020 Jan; 95():169-206. PubMed ID: 31654691
[TBL] [Abstract][Full Text] [Related]
31. Morphologic criteria for the prognosis of serous cystadenocarcinoma of the ovary.
Geppert M; Smyczek-Gargya B
Gynecol Obstet Invest; 1995; 39(2):136-40. PubMed ID: 7737584
[TBL] [Abstract][Full Text] [Related]
32. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
[TBL] [Abstract][Full Text] [Related]
33. TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.
El-Balat A; Schmeil I; Karn T; Becker S; Sänger N; Holtrich U; Arsenic R
Pathol Oncol Res; 2018 Apr; 24(2):277-282. PubMed ID: 28470574
[TBL] [Abstract][Full Text] [Related]
34. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
35. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.
Meinhold-Heerlein I; Fotopoulou C; Harter P; Kurzeder C; Mustea A; Wimberger P; Hauptmann S; Sehouli J
Arch Gynecol Obstet; 2016 Apr; 293(4):695-700. PubMed ID: 26894303
[TBL] [Abstract][Full Text] [Related]
36. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
[TBL] [Abstract][Full Text] [Related]
37. Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential.
Sangoi AR; Soslow RA; Teng NN; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):269-74. PubMed ID: 18223330
[TBL] [Abstract][Full Text] [Related]
38. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type.
Cuff J; Longacre TA
Am J Surg Pathol; 2012 May; 36(5):688-95. PubMed ID: 22498820
[TBL] [Abstract][Full Text] [Related]
39. EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas.
Gao W; Zhang Q; Wang Y; Wang J; Zhang S
APMIS; 2017 Feb; 125(2):122-127. PubMed ID: 28120491
[TBL] [Abstract][Full Text] [Related]
40. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
